相关实验视频

Updated: Jun 11, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

解读2-酸在癌症中的多方面的作用和临床影响

Jie Hao¹, Ziyi Huang², Siyue Zhang¹

¹Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China.

Pharmacological research

|September 30, 2024

概括

2-基酸盐 (2HG) 是一种驱动癌症的上代代谢物,通过抑制对表观遗传调节至关重要的酶. 了解2HG代谢和检测是开发新的癌症生物标志物和治疗方法的关键.

科学领域:

代谢性瘤学代谢性瘤学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
癌症生物学癌症生物学

背景情况:

2-基酸盐 (2HG) 是一种涉及瘤形成和进展的瘤代谢物.
升高的2HG水平是由IDH突变和酶失调造成的,在癌细胞中积累.
2HG在结构上模仿α-甲基酸盐 (αKG),竞争性抑制αKG依赖的二氧化酶 (αKGDs).

研究的目的:

综合审查2HG的代谢途径和癌症下游影响.
阐明2HG致癌活性的分子机制,重点关注表观遗传变化.
讨论目前和新兴的2HG检测方法及其作为临床生物标志物的潜力.

主要方法:

对代谢途径,分子机制和2HG检测技术的文献综述.
分析2HG诱导的瘤细胞和微环境表观遗传修饰的影响.
评估2HG作为诊断和治疗生物标志物的潜力.

主要成果:

累积的2HG抑制了αKGDs (例如,KDMs,TETs,EGLNs),导致广泛的表观遗传失调.
这些表观遗传变化有助于瘤的启动,进展和瘤微环境的调节.
现有各种2HG检测方法,并且正在不断开发新技术.

结论:

2HG是通过表观遗传重编程驱动癌症的关键性转移代谢物.
理解2HG的作用为癌症发展提供了洞察力,并提供了潜在的治疗点.
2HG作为癌症诊断和治疗监测的生物标志物具有显著的前景.

关键词:

2 - 酸二酸盐的使用情况癌症癌症癌症癌症这是一种IDH抑制剂.异酸脱基酶的异酸.代谢过程中的代谢.

更多相关视频

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...